Klinik Araştırma
BibTex RIS Kaynak Göster

Prevalence of Hepatitis B Serology and Reactivation in Rheumatology Patients Receiving Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs

Yıl 2024, Cilt: 6 Sayı: 3, 542 - 545, 24.09.2024
https://doi.org/10.37990/medr.1530674

Öz

Aim: This study sought to assess hepatitis B virus (HBV) serology and the incidence of HBV reactivation (HBVr) in rheumatology patients with resolved hepatitis B infection (HBsAg negative and HBcAb positive) who were undergoing treatment with biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs).
Material and Method: Data from rheumatology patients treated with b/tsDMARDs were retrospectively reviewed from the electronic records. The demographic data, the anti-rheumatic drugs used, and the hepatitis serologies (HBsAg, anti-HBc IgG, anti-HBs, and anti-HCV) of the patients were analyzed.
Results: The study included a total of 316 patients, of whom 217 (68.7%) were diagnosed with ankylosing spondylitis, 74 (23.4%) with rheumatoid arthritis, and 25 (7.9%) with psoriatic arthritis. Evaluation of the patients' viral serologies revealed that four (1.2%) were HBsAg positive, and 18 (5.7%) were HBsAg negative and HBcAb positive. Anti-HCV positivity was observed in one (0.3%) patient. All serologies were negative in 153 (48.4%) patients. No HBVr was detected during the follow-up of the patients.
Conclusion: The rate of resolved hepatitis B infection is relatively high in patients under rheumatologic follow-up. However, the use of biologics in these patients poses a low risk of HBVr.

Kaynakça

  • Mihai IR. Viral B and C hepatitis in rheumatic patients under biological therapy. Revista Medico-Chirurgicala. 2022;126:511-9.
  • Ozkan H. Epidemiology of Chronic Hepatitis B in Turkey. Euroasian J Hepatogastroenterol. 2018;8:73-4.
  • Singh JA, Saag KG, Bridges SL, et al. 2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1-26.
  • Spera AM. Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: pathogenesis, screening, prevention and treatment. World J Virol. 2022;11:275-82.
  • Ridola L, Zullo A, et al. Hepatitis B (HBV) reactivation in patients receiving biologic therapy for chronic inflammatory diseases in clinical practice. Ann Ist Super Sanita. 2021;57:244-8.
  • Kuo MH, Tseng CW, Lee CH, et al. Moderate risk of hepatitis B virus reactivation in HBsAg−/HBcAb+ carriers receiving rituximab for rheumatoid arthritis. Sci Rep. 2020;10:2456.
  • Conway R, Doran MF, O’Shea FD, et al. The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis. Clin Rheumatol. 2014;33:1823-7.
  • Cholongitas E, Haidich AB, Apostolidou-Kiouti F, et al. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol. 2018;31:480-90.
  • EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-85. J Hepatol. 2013;58:201.
  • Ogawa E, Wei MT, Nguyen MH. Hepatitis B virus reactivation potentiated by biologics. Infect Dis Clin North Am. 2020;34:341-58.
  • Kuo MH, Tseng C, Ko P, et al. HBV reactivation in HBsAg−/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs. Liver Int. 2024;44:497-507.
  • Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X2091264.
  • Fidan S, Capkın E, Arıca DA, et al. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy. Int J Rheum Dis. 2021;24:254-9.
  • Capkin E, Yazıcı A, Karkucak M, et al. Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study. Rheumatol Int. 2022;43:523-31.
  • Ergenc I, Kani HT, Karabacak M, et al. Biologic therapy carries a very low risk of reactivation in hepatitis B surface antigen-negative phase of hepatitis B. Turk J Gastroenterol. 2023;34:156-60.
  • Hong X, Xiao Y, Xu L, et al. Risk of hepatitis B reactivation in HBsAg−/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. Immun Inflamm Dis. 2023;11:e780.
  • Demirpençe Ö, Şahin H, Gümüş A, et al. HbsAg and antiHCV seroprevalence in an Eastern province of Turkey. Cumhuriyet Medical Journal. 2016;38:29-34.
  • Okay G, Biberci Keskin E, Akkoyunlu Y, et al. Evaluation of hepatitis B vaccine efficacy and factors affecting vaccine nonresponse in patients receiving anti-tumor necrosis factor agents. Eur J Gastroenterol Hepatol. 2021;33:1091-6.
Yıl 2024, Cilt: 6 Sayı: 3, 542 - 545, 24.09.2024
https://doi.org/10.37990/medr.1530674

Öz

Kaynakça

  • Mihai IR. Viral B and C hepatitis in rheumatic patients under biological therapy. Revista Medico-Chirurgicala. 2022;126:511-9.
  • Ozkan H. Epidemiology of Chronic Hepatitis B in Turkey. Euroasian J Hepatogastroenterol. 2018;8:73-4.
  • Singh JA, Saag KG, Bridges SL, et al. 2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1-26.
  • Spera AM. Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: pathogenesis, screening, prevention and treatment. World J Virol. 2022;11:275-82.
  • Ridola L, Zullo A, et al. Hepatitis B (HBV) reactivation in patients receiving biologic therapy for chronic inflammatory diseases in clinical practice. Ann Ist Super Sanita. 2021;57:244-8.
  • Kuo MH, Tseng CW, Lee CH, et al. Moderate risk of hepatitis B virus reactivation in HBsAg−/HBcAb+ carriers receiving rituximab for rheumatoid arthritis. Sci Rep. 2020;10:2456.
  • Conway R, Doran MF, O’Shea FD, et al. The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis. Clin Rheumatol. 2014;33:1823-7.
  • Cholongitas E, Haidich AB, Apostolidou-Kiouti F, et al. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol. 2018;31:480-90.
  • EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-85. J Hepatol. 2013;58:201.
  • Ogawa E, Wei MT, Nguyen MH. Hepatitis B virus reactivation potentiated by biologics. Infect Dis Clin North Am. 2020;34:341-58.
  • Kuo MH, Tseng C, Ko P, et al. HBV reactivation in HBsAg−/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs. Liver Int. 2024;44:497-507.
  • Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X2091264.
  • Fidan S, Capkın E, Arıca DA, et al. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy. Int J Rheum Dis. 2021;24:254-9.
  • Capkin E, Yazıcı A, Karkucak M, et al. Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study. Rheumatol Int. 2022;43:523-31.
  • Ergenc I, Kani HT, Karabacak M, et al. Biologic therapy carries a very low risk of reactivation in hepatitis B surface antigen-negative phase of hepatitis B. Turk J Gastroenterol. 2023;34:156-60.
  • Hong X, Xiao Y, Xu L, et al. Risk of hepatitis B reactivation in HBsAg−/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. Immun Inflamm Dis. 2023;11:e780.
  • Demirpençe Ö, Şahin H, Gümüş A, et al. HbsAg and antiHCV seroprevalence in an Eastern province of Turkey. Cumhuriyet Medical Journal. 2016;38:29-34.
  • Okay G, Biberci Keskin E, Akkoyunlu Y, et al. Evaluation of hepatitis B vaccine efficacy and factors affecting vaccine nonresponse in patients receiving anti-tumor necrosis factor agents. Eur J Gastroenterol Hepatol. 2021;33:1091-6.
Toplam 18 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Bulaşıcı Hastalıklar, Romatoloji ve Artrit
Bölüm Özgün Makaleler
Yazarlar

Derya Çırakoğlu 0000-0002-7827-8032

Emine Serap Yılmaz 0000-0001-5308-4488

Yayımlanma Tarihi 24 Eylül 2024
Gönderilme Tarihi 9 Ağustos 2024
Kabul Tarihi 9 Eylül 2024
Yayımlandığı Sayı Yıl 2024 Cilt: 6 Sayı: 3

Kaynak Göster

AMA Çırakoğlu D, Yılmaz ES. Prevalence of Hepatitis B Serology and Reactivation in Rheumatology Patients Receiving Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs. Med Records. Eylül 2024;6(3):542-545. doi:10.37990/medr.1530674

 Chief Editors

Assoc. Prof. Zülal Öner
Address: İzmir Bakırçay University, Department of Anatomy, İzmir, Turkey

Assoc. Prof. Deniz Şenol
Address: Düzce University, Department of Anatomy, Düzce, Turkey

E-mail: medrecsjournal@gmail.com

Publisher:
Medical Records Association (Tıbbi Kayıtlar Derneği)
Address: Orhangazi Neighborhood, 440th Street,
Green Life Complex, Block B, Floor 3, No. 69
Düzce, Türkiye
Web: www.tibbikayitlar.org.tr

Publication Support: 

Effect Publishing & Agency
Phone: + 90 (540) 035 44 35
E-mail: info@effectpublishing.com
Address: Akdeniz Neighborhood, Şehit Fethi Bey Street,
No: 66/B, Ground floor, 35210 Konak/İzmir, Türkiye
web: www.effectpublishing.com